Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
The Centers for Disease Control & Prevention predict that by 2050, if current trends continue, 1 in 3 adults in the U.S. will have diabetes. The digital diabetes management company GlucoMe hopes it can develop a smarter healthcare model t0 fit this growing patient population.
“Diabetes is an inter-world epidemic – a pandemic – and the number of patients is constantly increasing,” co-founder & CEO Yiftah Ben Aharon told Drug Delivery Business News. “So, it doesn’t make sense to keep the current treatment model and current care model the same.” Read more
Penumbra said today that it priced a public offering worth nearly $99 million, not including an underwriter’s option worth nearly $15 million.
Alameda, Calif.-based Penumbra makes a line of instruments designed for neurovascular and peripheral vascular procedures, including stroke revascularization, embolization and thrombectomy. Read more
Data presented at ACC 2017 showed that Boston Scientific’s’ Synergy bioabsorbable polymer drug-eluting stent was as efficacious as the company’s Promus Element Plus drug-eluting stent system, with a lower relative rate of stent thrombosis.
The 3-year Evolve II trial enrolled 1,684 patients with native coronary artery lesions and randomized patients to receive either the Synergy or Promus stent. The primary endpoint was target lesion failure at 12 months. Read more
A study comparing surgical valve replacement with transcatheter aortic valve replacement using the CoreValve device made by Medtronic showed that the TAVR device was as safe as surgery in intermediate-risk patients, according to data presented today at ACC 2017.
Two-year data from the 1,657-patient Surtavi study, presented at ACC 2017 and published in the New England Journal of Medicine, showed non-inferiority for the CoreValve implant for an endpoint combining all-cause mortality and disabling stroke, with the TAVR device showing a 12.6% rate compared with 14% for surgical intervention. Read more
Boston Scientific said yesterday that a U.K. healthcare agency backed its EnduraLife batteries for cardiac resynchronization therapy defibrillators, citing the savings offering by reduced replacement procedures.
The guidance from Great Britain’s National Institute for Health & Care Excellence concluded that the EnduraLife technology would improve outcomes and create some $7.4 million (£6 million) in savings over 5 years, Boston Scientific said. Read more